Jon R. Levine, President and CEO of MariMed Inc., filed a Form 4 on November 9, 2026, reporting the vesting of 75,000 restricted stock units and a related tax withholding transaction on November 7, 2026.
Key Highlights
- RSU conversion: 75,000 restricted stock units, originally granted on November 7, 2023, converted to common stock on a one-for-one basis at a price of $0 on November 7, 2026.
- Tax withholding: 22,013 shares of common stock were withheld by the issuer to satisfy tax withholding obligations connected to the RSU vesting, at a price of $0.067 per share.
- Direct ownership after transactions: Levine directly holds 21,440,780 shares of MariMed common stock following the reported transactions.
- Indirect ownership: An additional 6,684,640 shares are held indirectly by Levine's spouse, though the filing states he "disclaims beneficial ownership of these securities."
- Grant fully vested: According to the filing, "there are no remaining RSUs under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person."
- Roles: Levine is identified as a Director, 10% Owner, and President and CEO of MariMed Inc. (OTC:MRMD).
MariMed CEO Completes Final Vesting of 2023 RSU Grant
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Jon R. Levine, President and CEO of MariMed Inc. (OTC:MRMD), reported two transactions in common stock on November 7, 2026. The first was the conversion of 75,000 restricted stock units into common stock at $0, reflected under transaction code "M." The RSUs had been granted on November 7, 2023, and the filing states no RSUs remain under that grant.
Concurrent with the vesting, the issuer withheld 22,013 shares under transaction code "F" at a price of $0.067 per share to cover Levine's tax withholding obligations. After both transactions, Levine's direct beneficial ownership stands at 21,440,780 shares of MariMed common stock, the filing disclosed. An additional 6,684,640 shares are held indirectly through his spouse, but the filing notes that Levine "disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."
The filing was signed by Jon R. Levine on November 9, 2026, and was submitted as an individual filing by one reporting person. No derivative securities remain outstanding under the referenced RSU grant following these transactions.
What Was Disclosed
MariMed CEO Jon R. Levine reported the full vesting of a 75,000-unit RSU grant originally made in November 2023, with 22,013 shares withheld for taxes at $0.067 each, leaving him with 21,440,780 shares held directly.




Please wait processing your request...